http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Yuji Maehata ),( Shotaro Nakamura ),( Motohiro Esaki ),( Fumie Ikeda ),( Tomohiko Moriyama ),( Risa Hida ),( Ema Washio ),( Junji Umeno ),( Minako Hirahashi ),( Takanari Kitazono ),( Takayuki Matsum 대한간학회 2017 Gut and Liver Vol.11 No.5
Background/Aims: Gastric cancers develop even after suc-cessful Helicobacter pylori eradication. We aimed to clarify the characteristics of early gastric cancers discovered after H. pylori eradication. Methods: A total of 1,053 patients with early gastric cancer treated by endoscopic submucosal dis-section were included. After matching the propensity score, we retrospectively investigated the clinicopathological fea-tures of 192 patients, including 96 patients who had under-gone successful H. pylori eradication (Hp-eradicated group) and 96 patients who had active H. pylori infection (Hp-positive group). Results: In the Hp-eradicated group, early gastric cancers were discovered 1 to 15 years (median, 4.1 years) after H. pylori eradication. Compared with Hp-positive pa-tients, Hp-eradicated patients showed a more frequently de-pressed configuration (81% vs 53%, respectively, p<0.0001) and a higher trend toward submucosal invasion (18% vs 8%, respectively, p=0.051). A multivariable analysis revealed the macroscopic depressed type to be characteristics of early gastric cancers after H. pylori eradication. Among patients in the Hp-eradicated group, metachronous cancers showed less frequent depressed lesions (68% vs 84%, respectively, p=0.049) and smaller tumor sizes (median, 11 mm vs 14 mm, respectively, p=0.014) than primary cancers. Conclu-sions: Early gastric cancers after H. pylori eradication are characterized by a depressed configuration. Careful follow- up endoscopies are necessary after H. pylori eradication. (Gut Liver 2017;11:628-634)
Satoko Yamaguchi,Shunichi Yanai,Shotaro Nakamura,Keisuke Kawasaki,Makoto Eizuka,Noriyuki Uesugi,Tamotsu Sugai,Junji Umeno,Motohiro Esaki,Takayuki Matsumoto 대한장연구학회 2018 Intestinal Research Vol.16 No.3
Background/Aims: We recently identified recessive mutations in the solute carrier organic anion transporter family member 2A1 gene (SLCO2A1) as causative variants of chronic enteropathy associated with SLCO2A1 (CEAS). The aim of this study was to evaluate SLCO2A1 protein expression in the intestinal tissues of patients with CEAS, intestinal Behçet’s disease (BD), simple ulcer (SU), and Crohn’s disease (CD). Methods: Immunohistochemical staining using a polyclonal anti-SLCO2A1 antibody was performed on the resected intestinal specimens from 13 cases of CD, 9 cases of intestinal BD/SU, and 3 cases of CEAS. The extent of SLCO2A1 expression was determined by counting positively-staining vascular endothelial cells and scored as 0 (no cells), 1 (1%−30% cells), 2 (31%−60%), or 3 (>60%). The intensity of SLCO2A1 expression was scored either as 0 (negative), 1 (intermediate), or 2 (strong). The extent score and intensity score were summed for the final score of 0, 2, 3, 4, or 5. Results: SLCO2A1 protein expression was observed in 1 of 3 cases of CEAS (33%), all 13 cases of CD (100%), and all 9 cases of BD/SU (100%). The mean final expression scores of CEAS, CD, and BD/SU were 1.6 (range, 0−5), 4.8 (range, 4−5), and 4.3 (range, 4−5), respectively. The final expression score in CEAS was significantly lower than in CD (P=0.03). Conclusions: Immunohistochemical staining of the SLCO2A1 protein is considered useful to distinguish CEAS from other inflammatory bowel diseases.
Distinction between Chronic Enteropathy Associated with the SLCO2A1 Gene and Crohn’s Disease
Shunichi Yanai,Satoko Yamaguchi,Shotaro Nakamura,Keisuke Kawasaki,Yosuke Toya,Noriyuki Yamada,Makoto Eizuka,Noriyuki Uesugi,Junji Umeno,Motohiro Esaki,Eiko Okimoto,Shunji Ishihara,Tamotsu Sugai,Takayu 거트앤리버 소화기연관학회협의회 2019 Gut and Liver Vol.13 No.1
Background/Aims: We recently identified recessive mutations in the solute carrier organic anion transporter family member 2A1 gene (SLCO2A1 ) as causative variants of chronic nonspecific multiple ulcers of the small intestine (chronic enteropathy associated with SLCO2A1, CEAS). The aim of this study was to investigate the gastroduodenal expression of the SLCO2A1 protein in patients with CEAS and Crohn’s disease (CD). Methods: Immunohistochemical staining for SLCO2A1 was performed with a polyclonal antibody, HPA013742, on gastroduodenal tissues obtained by endoscopic biopsy from four patients with CEAS and 29 patients with CD. Results: The expression of SLCO2A1 was observed in one of four patients (25%) with CEAS and in all 29 patients (100%) with CD (p<0.001). The three patients with CEAS without SLCO2A1 expression had a homozygous splice-site mutation in SLCO2A1, c.1461+1G>C (exon 7) or c.940+1G>A (exon 10). The remaining one CEAS patient with positive expression of SLCO2A1 had compound heterozygous c.664G>A and c.1807C>T mutations. Conclusions: Immunohistochemical staining for SLCO2A1 in gastroduodenal tissues obtained by endoscopic biopsy is considered useful for the distinction of CEAS from CD.
( Takahiro Gonai ),( Keisuke Kawasaki ),( Shotaro Nakamura ),( Shunichi Yanai ),( Risaburo Akasaka ),( Kunihiko Sato ),( Yousuke Toya ),( Kensuke Asakura ),( Jun Urushikubo ),( Yasuko Fujita ),( Makot 대한장연구학회 2020 Intestinal Research Vol.18 No.1
Background/Aims: Magnifying endoscopic classification systems, such as the Japan narrow-band imaging (NBI) Expert Team (JNET) classification, have been widely used for predicting the histologic diagnosis and invasion depth of colorectal epithelial tumors. However, disagreement exists among observers regarding magnifying endoscopic diagnosis, because these classification systems are subjective. We herein investigated the utility of endoscopic microvascular density (eMVD) calculated from magnifying NBI endoscopic images in colorectal tumors. Methods: We reviewed magnifying NBI endoscopic images from 169 colorectal epithelial tumors (97 adenomas, 72 carcinomas/high-grade dysplasias) resected endoscopically or surgically. The eMVD on magnifying NBI endoscopic images was evaluated using image-editing software, and relationships between eMVD and clinical, endoscopic, and pathological findings were retrospectively analyzed. Results: The eMVD in carcinomas (0.152±0.079) was significantly higher than that in adenomas (0.119±0.059, P<0.05). The best cutoff value for distinguishing carcinoma from adenoma was 0.133. Sensitivity, specificity, and accuracy were 56.9%, 67.0%, and 62.7%, respectively. In addition, JNET type 2B tumors showed significantly higher eMVD (0.162±0.079) compared to type 2A tumors (0.111±0.050, P<0.05). Conclusions: The eMVD as determined by magnifying NBI endoscopy is considered to be a possible objective indicator for differentiating colorectal carcinomas from adenomas. (Intest Res 2020;18:107-114)